Testosterone FDA Approved

What It Is

Testosterone is the primary endogenous male sex hormone and the prototypical anabolic-androgenic steroid. It is biosynthesized from cholesterol primarily in testicular Leydig cells (men) and in smaller quantities from ovaries and adrenal glands (women). Endogenous serum total testosterone in healthy adult men typically ranges 300–1,000 ng/dL, with free testosterone 5–15 ng/dL; both decline gradually from the 4th decade onward at approximately 1–2% per year.

Therapeutically, testosterone is supplied as a series of esterified derivatives (cypionate, enanthate, propionate, undecanoate) or as transdermal gels, pellets, and more recently subcutaneous autoinjectors. Esterification delays hydrolysis and extends the duration of action. Testosterone cypionate and enanthate — the two dominant US intramuscular injectables — have apparent half-lives of approximately 8 days and 4.5–7 days, respectively, enabling once-weekly to twice-weekly dosing. Testosterone propionate has a 2-day half-life and is used for more rapid onset/offset but requires more frequent injection.

Testosterone replacement therapy (TRT) is FDA-approved for the treatment of hypogonadism in men. It is the most-studied anabolic-androgenic steroid in human clinical populations, with a clinical evidence base spanning over 80 years and thousands of randomized controlled trials. The 2018 Endocrine Society Clinical Practice Guideline (Bhasin et al., J Clin Endocrinol Metab 2018; PMID 29562364) is the authoritative guidance document for US prescribing practice. The 2023 TRAVERSE trial (Lincoff et al., NEJM; PMID 37326322), enrolling 5,246 middle-aged and older men with hypogonadism and elevated cardiovascular risk, established that TRT does not increase major adverse cardiovascular events versus placebo — resolving two decades of cardiovascular-safety debate but also documenting an atrial fibrillation signal that informs modern risk-benefit conversations.

In the Kalios compound context, testosterone is included because it is the foundational reference point for male hormonal optimization protocols. Most peptide protocols in men — GH secretagogues, kisspeptin, PT-141, tesamorelin — either assume baseline testosterone is normal or are layered onto a TRT foundation. Understanding testosterone is therefore prerequisite to understanding most male-specific peptide protocols. TRT is a legitimate FDA-regulated prescription, is scheduled under DEA Schedule III, and requires medical supervision; it is fundamentally different from the gray-market research peptides that comprise most of this database.

Mechanism of Action

Testosterone is a steroid hormone acting through the androgen receptor (AR) and, via aromatization, through the estrogen receptor (ER) pathway as well. Understanding testosterone's mechanism requires understanding both its direct androgen effects and its metabolic downstream (DHT, estradiol).

• Androgen receptor (AR) activation — Testosterone and its 5α-reduced metabolite dihydrotestosterone (DHT) bind the androgen receptor, a nuclear receptor in the steroid hormone receptor superfamily. AR activation drives gene transcription of androgen-responsive elements, which modulate protein synthesis, skeletal muscle hypertrophy, bone density, erythropoiesis, libido, aggression, spatial cognition, and hundreds of other physiological endpoints.
• 5α-reductase conversion to DHT — Approximately 5% of circulating testosterone is converted to DHT by 5α-reductase (types I and II). DHT has ~3x the androgen receptor binding affinity of testosterone. It mediates androgen effects in skin (sebaceous glands, beard/body hair), prostate, and scalp (male pattern baldness). 5α-reductase inhibition (finasteride, dutasteride) reduces DHT while preserving testosterone.
• Aromatization to estradiol (E2) — Approximately 0.3% of circulating testosterone is converted to estradiol by the aromatase enzyme (CYP19A1), expressed in adipose, bone, brain, and gonads. Estradiol mediates important male physiology: bone mineral density, cardiovascular function, libido, and mood. Excessive estradiol causes gynecomastia, emotional lability, and water retention; too little causes bone loss, joint pain, and reduced libido.
• Skeletal muscle protein synthesis — Testosterone upregulates muscle protein synthesis, reduces muscle protein breakdown, and shifts satellite cell commitment toward the myogenic lineage. Dose-response is linear with serum testosterone level across physiologic and supraphysiologic ranges (Bhasin et al., NEJM 1996; PMID 8637535).
• Erythropoiesis (hematocrit elevation) — Direct bone marrow effect plus suppression of hepcidin → increased iron availability → increased red cell mass. Clinically relevant because TRT commonly elevates hematocrit into pre-polycythemic or polycythemic range requiring dose adjustment, phlebotomy, or both.
• HPG axis suppression — Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH/FSH secretion via negative feedback, shutting down endogenous testicular testosterone production and spermatogenesis. This is the mechanistic basis for the infertility side effect and for HCG adjunct therapy (which bypasses HPG by directly stimulating testicular LH receptors).
• Bone mineral density — Both direct AR effects and aromatization-dependent estradiol effects contribute to bone density maintenance. Men with persistent hypogonadism develop osteopenia and osteoporosis over years to decades.
• CNS effects — Testosterone affects mood, libido, aggression, spatial cognition, and executive function via both AR and aromatization-dependent ER pathways in limbic and cortical regions.
• Cardiovascular effects — Testosterone modestly reduces adiposity, improves insulin sensitivity, and affects vascular function. The long-disputed cardiovascular safety question was definitively addressed by TRAVERSE (Lincoff 2023), which showed no increase in MACE with physiologic TRT but did document a slight increase in atrial fibrillation and nonfatal arrhythmias.
• Prostate effects — Prostate responds to DHT. Long-held concerns about TRT "causing" prostate cancer have not been borne out by modern meta-analytic and TRAVERSE data, but accelerating growth of pre-existing prostate cancer remains an absolute contraindication for TRT. PSA monitoring is mandatory.

What the Research Shows

Testosterone is among the most rigorously studied bioactive compounds in medicine. Key findings across decades of research:

• Dose-response for muscle (Bhasin et al., NEJM 1996; PMID 8637535) — Classical study demonstrating dose-response relationship between testosterone administration and muscle mass/strength in healthy young men, with effects independent of training status. Foundational demonstration of AR-mediated hypertrophy.
• Age-related decline (Harman et al., J Clin Endocrinol Metab 2001; PMID 11158037) — Baltimore Longitudinal Study of Aging. Demonstrated gradual testosterone decline with age, ~1–2% per year from 4th decade.
• TRT effects (T Trials, Snyder et al., NEJM 2016) — Seven coordinated trials in hypogonadal men over 65. Showed TRT improved sexual function, physical function, vitality, and mood; modest effects on anemia and bone density; neutral effect on cognition.
• Cardiovascular safety (TRAVERSE — Lincoff et al., NEJM 2023; PMID 37326322) — 5,246 men aged 45–80 with hypogonadism and CV risk; transdermal T vs placebo. Primary endpoint: noninferiority for MACE. Testosterone met noninferiority for MACE. Atrial fibrillation and nonfatal arrhythmia modestly increased.
• Endocrine Society 2018 Guidelines (Bhasin et al., J Clin Endocrinol Metab 2018; PMID 29562364) — Definitive US prescribing guidance. Recommends treatment only when total T <300 ng/dL (confirmed twice, morning draw) with hypogonadism symptoms. Target mid-normal range (300–600 ng/dL) at steady state.
• Metabolic effects meta-analysis — TRT modestly improves fasting glucose, HbA1c, insulin resistance, and visceral adiposity in hypogonadal men. Small but measurable body-composition improvements.
• Bone density effects — TRT in hypogonadal men improves bone mineral density, particularly at the spine. Effect size smaller than bisphosphonates.
• Sexual function endpoints — Consistent improvement in libido, sexual activity, and erectile function in hypogonadal men across multiple trials. Effect size moderate.
• Prostate (long debate, current consensus) — Modern meta-analytic data and TRAVERSE do not show increased prostate cancer incidence with TRT in men without pre-existing disease. Accelerating pre-existing occult cancer remains a concern; PSA monitoring is standard.
• Cognitive endpoints — Mixed. TRT in hypogonadal men modestly improves verbal memory in some trials; other cognitive domains less consistently.
• Mood and depression — TRT can improve mood in hypogonadal men with depressive symptoms. Not a substitute for antidepressants in non-hypogonadal men with depression.
• Fertility preservation / HCG — Concurrent HCG (250–500 IU 2–3x/wk) during TRT maintains testicular size and spermatogenesis. Standard practice for men intending future fertility.
• Subcutaneous vs intramuscular — Modern research (Kaminetsky et al., 2019) demonstrates SubQ testosterone delivery produces equivalent or superior steady-state levels with less peak-to-trough variability than IM; broadly accepted in modern men's health clinics.

Human Data

The human TRT evidence base is vast. Key studies:

• Bhasin 1996 NEJM — Dose-response for T and muscle in healthy men.
• T Trials (2010s) — Seven coordinated NIH-funded trials in older hypogonadal men.
• TRAVERSE (2023; NEJM; PMID 37326322) — Cardiovascular safety pivotal trial.
• TIMES2 (Jones et al.) — TRT in men with T2D and metabolic syndrome.
• Registry studies — Long-term observational data on TRT outcomes across large health-system populations.
• Kaminetsky 2019 SubQ autoinjector study — Phase 2 subcutaneous T enanthate autoinjector validation (Xyosted pathway).
• Harman 2001 BLSA — Longitudinal natural history data on age-related T decline.
• Pharmacokinetic studies across ester types — Comparative PK of cypionate, enanthate, undecanoate, propionate, and transdermal formulations.
• Hematocrit monitoring literature — Multiple trials documenting TRT erythropoietic effect and polycythemia management strategies.
• PSA monitoring studies — Standard protocols for PSA surveillance during TRT.
• Fertility / HCG adjunct trials — Validation of HCG for preserving spermatogenesis during TRT.

Dosing from the Literature

Dosing below reflects the Endocrine Society Clinical Practice Guideline (Bhasin 2018) and modern men's-health clinic practice.

Reconstitution & Storage

Testosterone cypionate and enanthate are supplied as oil-based injectable solutions in multi-dose vials (1 mL or 10 mL). No reconstitution is required — the compound is dissolved in a vegetable-oil carrier (typically cottonseed, sesame, or grapeseed oil).

• Storage — Room temperature (20–25°C), protected from light. Do not refrigerate (oil may thicken). Do not freeze.
• Warming before injection — If oil is viscous, warm vial in hand or warm water bath. Do not microwave.
• Injection technique (IM) — 22–25G needle for IM into glute, ventrogluteal, or vastus lateralis. Aspirate to confirm not in a vessel (debated; many clinicians skip).
• Injection technique (SubQ) — 27–29G insulin syringe, 45° SubQ into abdomen or thigh. Smaller volumes (0.25–0.5 mL); slower push.
• Injection frequency trade-off — More frequent, smaller injections (e.g., 50 mg 2x/week SubQ) produce more stable levels and lower peak estradiol excursions than less frequent, larger injections.
• Site rotation — Critical to avoid chronic local tissue irritation or nodules.
• Inspection — Clear, faintly yellow oil. Discard if cloudy, discolored, or contaminated.

→ Use the Kalios Peptide Calculator for exact injection volumes

Side Effects & Risks

Testosterone has the most comprehensively characterized side-effect profile of any anabolic steroid. The TRAVERSE trial clarified the cardiovascular safety picture; the rest of the profile is well-established across decades of clinical use.

• Erythrocytosis / polycythemia — Most common clinically significant side effect. TRT raises hematocrit; ~5–15% of patients require phlebotomy or dose reduction. Target hematocrit <54%. Higher with IM than transdermal.
• Fertility suppression — HPG-axis suppression causes reduced or absent spermatogenesis in most men. Reversible with cessation (months to year) or preserved with concurrent HCG 250–500 IU 2–3x/wk.
• Testicular atrophy — Shrinkage from HPG suppression. Mitigated by HCG.
• Estradiol elevation (aromatization) — Increased aromatization at supra-physiologic levels. High E2 causes water retention, gynecomastia, mood lability, and libido changes. Monitoring and management (aromatase inhibitors at very high doses, dose reduction at physiologic doses) are standard.
• Gynecomastia — Breast tissue development from estradiol elevation. Preventable with dose/E2 management; surgery required if glandular tissue has formed.
• Acne and seborrheic dermatitis — DHT-driven sebaceous gland activation. Dose-dependent.
• Androgenetic alopecia acceleration — In genetically susceptible men, DHT drives male pattern baldness. 5α-reductase inhibition (finasteride) can counteract but introduces its own side-effect profile.
• Prostate effects — PSA rise is common. Modern evidence (TRAVERSE, meta-analyses) does not show increased new prostate cancer incidence; accelerating occult pre-existing disease is still a concern. Monitor PSA.
• Cardiovascular (TRAVERSE summary) — No MACE increase. Small increase in atrial fibrillation / nonfatal arrhythmias. No increase in MI, stroke, CV death at physiologic doses.
• Sleep apnea exacerbation — Testosterone worsens obstructive sleep apnea in susceptible individuals.
• Mood changes — Generally improvement in hypogonadal men; occasional irritability, aggression at supra-physiologic doses.
• Dyslipidemia (supra-physiologic only) — Oral T methyltestosterone was hepatotoxic; injectable physiologic TRT has minimal lipid effect, but supra-physiologic doses reduce HDL and increase LDL.
• Liver toxicity (orals only) — 17α-alkylated oral steroids (methyltestosterone, fluoxymesterone) are hepatotoxic; modern oral T undecanoate and injectable esters are not.
• Skin-to-skin transfer (gels) — Transdermal gels can transfer to partners and children by skin contact. Wash hands after application and cover application site.
• Contraindications — Prostate cancer, breast cancer, hematocrit >54%, untreated severe OSA, uncontrolled CHF, active fertility plans without HCG adjunct.
• WADA / competitive sport — Banned under S1 (Anabolic Agents). Detection is standard via urinary T/E ratio and Carbon Isotope Ratio Mass Spectrometry.
• DEA Schedule III — Controlled substance in the US. Prescription-only; possession without prescription is a federal crime.

Supportive Nutrition & Supplements

TRT is most effective when lifestyle and nutritional inputs support its mechanism of action.

• Protein (1.6–2.2 g/kg/day) — TRT amplifies AR-mediated muscle protein synthesis; protein substrate is required for the hypertrophic response to manifest.
• Resistance training — Dose-response for TRT + training is substantially better than TRT alone. 2–4 sessions/week minimum of progressive compound lifting.
• Vitamin D (target 40–60 ng/mL) — Low vitamin D is associated with low testosterone independently; correcting deficiency is a high-yield adjunct.
• Zinc (15–25 mg/day) — Cofactor for testosterone synthesis. Deficiency causes hypogonadism; supplementation above normal zinc status does not raise T further.
• Magnesium (300–400 mg/day) — Supports free-T bioavailability and sleep quality.
• Boron (3–10 mg/day) — Smaller evidence base; may modestly increase free testosterone by reducing SHBG binding.
• Creatine (3–5 g/day) — Synergistic with TRT for strength and lean-mass gains.
• Omega-3 (2–3 g EPA/DHA) — General anti-inflammatory + cardiovascular support relevant to long-term TRT.
• Sleep (7–9 hours) — Chronic sleep restriction reduces testosterone ~10–15% in young men. TRT doesn't rescue a broken sleep pattern; sleep fundamentals matter.
• Body composition / body fat — Visceral adiposity increases aromatase activity → more E2, less T. Fat loss directly improves the endogenous T:E2 ratio.
• Things to avoid — Chronic alcohol (suppresses T and raises E2), chronic opioid use (potent HPG suppressor), chronic high-dose corticosteroid (HPG suppressor), endocrine-disrupting chemicals in consumer products (phthalates, BPA — evidence moderate but trending stronger).

What to Expect — Timeline

Individual response varies. The following synthesizes clinical trial data and clinician-observed patterns.

• Week 1–2 — Minor subjective changes — sometimes improved energy or mood. Hematologic and body composition changes not yet apparent.
• Week 3–6 — Libido and morning erections often improve earliest (weeks 3–6). Serum T reaches steady state within 4–6 half-lives (~4–5 weeks for cypionate).
• Week 6–12 — Mood, energy, and sexual function typically stabilize at the new baseline. Hematocrit beginning to rise; check at 3 months.
• Month 3–6 — Body composition changes visible: modest lean-mass gain, modest fat-mass reduction, particularly when combined with resistance training.
• Month 6–12 — Full expression of body composition effect. Bone density changes measurable at 12+ months. Hematocrit stabilizes at new steady state.
• Year 1+ — Long-term sustained benefits. Cardiovascular, metabolic, and sexual function maintained. Long-term monitoring becomes the ongoing requirement.
• Cessation — Endogenous HPG axis typically recovers within 3–12 months of discontinuation in men without primary hypogonadism. PCT (post-cycle therapy) protocols with hCG + SERMs accelerate recovery when fertility is a priority after cycle use.
• Non-responders — Rare for the pure hormonal endpoint (T levels rise predictably). Subjective non-response is more common and usually reflects: underlying depression not attributable to T, untreated sleep apnea, inadequate lifestyle inputs, or unrealistic expectations calibrated to steroid-cycle forum content.
• If you feel worse — Headaches, irritability, water retention, acne, breast tenderness — typically reflects high E2 or supra-physiologic T. Check labs, adjust dose or add management. Persistent symptoms warrant cessation and evaluation.

Quick Compare — Testosterone vs HCG vs Enclomiphene vs Nandrolone

The most relevant comparators for testosterone in a male-hormonal-optimization context are (a) HCG (restores endogenous T without HPG suppression), (b) enclomiphene (SERM that raises endogenous T), and (c) nandrolone (a non-aromatizing anabolic steroid used off-label alongside TRT).

Practical interpretation:

• Testosterone vs HCG — Not substitutes. HCG stimulates Leydig cells to produce endogenous T; TRT replaces T directly. HCG used as adjunct to TRT for fertility/testicular preservation.
• Testosterone vs enclomiphene — For younger men with secondary hypogonadism who want to avoid HPG suppression, enclomiphene raises endogenous T without shutting down the axis. Works only if the pituitary can respond.
• Testosterone vs nandrolone — Different AAS profiles. Nandrolone has less aromatization (less E2) but strong HPG suppression and well-documented sexual dysfunction in a subset. Non-substitute; sometimes added to TRT at moderate doses by men's-health clinics for joint and lean-mass benefits.
• Best-fit protocol — Confirmed primary hypogonadism → TRT. Secondary hypogonadism with fertility preservation → enclomiphene or TRT + HCG. Fertility-neutral hypogonadism → TRT alone. Performance-focused use outside hypogonadism → separate category with different risk-benefit.

→ See HCG profile  •  → See Enclomiphene profile  •  → See Nandrolone profile

Practical User Notes

• Get confirmed diagnosis first — Two fasting morning total T <300 ng/dL plus hypogonadism symptoms is the Endocrine Society diagnostic standard. Single low reading or "low-normal" is not automatic TRT indication.
• Know your baseline — Full hormonal and metabolic panel before initiating. Without baseline, you can't track change.
• Frequency over dose — 50 mg 2x/week SubQ produces more stable levels and fewer estradiol excursions than 100 mg 1x/week IM. Modern men's-health practice increasingly favors the more-frequent-smaller-dose approach.
• SubQ works as well as IM — Multiple trials validate SubQ TRT. Less pain, finer needles, easier home administration.
• HCG if fertility matters — Any man on TRT with potential future paternity goals should consider HCG adjunct to preserve spermatogenesis.
• Don't aggressively suppress E2 — Over-aromatase-inhibition causes joint pain, fatigue, libido decline, and bone loss. At physiologic TRT, most men do not need AI.
• Hematocrit management — Hydration, donate blood if >52%, reduce dose or frequency if persistently >54%.
• PSA monitoring is not optional — Baseline + annual at minimum. More frequent in men >50 or with prostate risk factors.
• Stick with one formulation — Switching cypionate ↔ enanthate is fine pharmacokinetically; switching IM ↔ transdermal changes levels significantly.
• Consistency of timing — Same day, same time, fixed interval. Predictable serum patterns support predictable monitoring.
• Track feel alongside labs — Labs without symptoms and symptoms without labs both lead to suboptimal dose management. Track both.
• Expect the system to reach steady-state in ~4–6 weeks — Don't over-adjust during the first month. Labs at 8–12 weeks are more informative.
• Red flags to stop and evaluate — Severe headache, vision changes, chest pain, new dyspnea, sudden mood/aggression change, persistent high hematocrit (>54% after phlebotomy), or any new PSA concern.

Bloodwork & Monitoring

TRT monitoring is standardized and non-negotiable. The Endocrine Society guideline provides the baseline structure; men's health clinics often add monitoring beyond the minimum.

• Pre-TRT baseline — Two fasting morning total testosterone, free T, SHBG, E2 (sensitive assay), LH, FSH, prolactin, CBC (hematocrit), CMP, PSA (men >40), lipid panel, HbA1c.
• Repeat at 3 months — Total T (midway between IM doses), hematocrit, E2, PSA.
• Repeat at 6 months — Full baseline workup.
• Then every 6–12 months — Total T, hematocrit, PSA, lipid panel, CMP.
• Hematocrit >54% — Dose reduce, extend injection interval, or phlebotomize.
• PSA rise >1.4 ng/mL in first year or >4 ng/mL absolute — Urology referral.
• E2 >50 pg/mL + symptomatic — Dose reduce or aromatase inhibitor (low-dose anastrozole 0.25–0.5 mg 1–2x/week).
• Bone density (DEXA) — Baseline in men with established hypogonadism; repeat at 1–2 years.
• Sleep apnea screen — STOP-BANG or Epworth if symptomatic.
• Fertility workup — If future paternity planned: semen analysis before TRT; consider HCG throughout TRT or FSH stimulation for fertility preservation.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching testosterone often also look at these:

Next Steps

Key References

1. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. PMID: 37326322. DOI: 10.1056/NEJMoa2215025.
2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364.
3. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7. PMID: 8637535.
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037.
5. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521.
6. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. PMID: 26797061. PMC4721027.
7. Morgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016;91(7):881-896. PMID: 27313122.
8. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837. PMID: 21386088.
9. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. PMID: 20592293.
10. Pharmacology of Testosterone Replacement Therapy Preparations. Transl Androl Urol. 2016;5(6):834-843. PMC5182226.
11. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838.
12. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675-685. PMID: 21753068.
13. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. PMID: 20554979.
14. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis. Mayo Clin Proc. 2007;82(1):29-39. PMID: 17285783.
15. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. PMID: 28078214.
16. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PMID: 18160461.
17. Page ST, Amory JK, Bremner WJ. Advances in male contraception. Endocr Rev. 2008;29(4):465-493. PMID: 18436704.
18. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923.
19. WADA. 2025 Prohibited List. Section S1 — Anabolic Agents. World Anti-Doping Agency.
20. US Drug Enforcement Administration. Schedules of Controlled Substances. Testosterone — Schedule III. Anabolic Steroids Control Act.